Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Abstract Objectives Bispecific antibodies targeting CD47 and PD‐L1 (CD47 × PD‐L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti‐CD47‐mediated toxicity, the effect of combined innate and adaptive immune activation on protective tumor‐resident CD8+ T cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan N Christo, Keely M McDonald, Thomas N Burn, Nadia Kurd, Jessica Stanfield, Megan M Kaneda, Ruth Seelige, Christopher P Dillon, Timothy S Fisher, Bas Baaten, Laura K Mackay
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Clinical & Translational Immunology
Subjects:
adaptive immunity
CD47
CD8+ T cells
immune checkpoint blockade
immunotherapy
tumor‐resident CD8+ T cells
Online Access:https://doi.org/10.1002/cti2.70014
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cti2.70014

Similar Items